Study finds low rates of baseline BMD testing among older women with breast cancer

NewsGuard 100/100 Score

Aromatase inhibitors (AIs)—drugs that stop the production of estrogen in women—are standard adjuvant therapy for post-menopausal women with hormone-receptor positive breast cancer. AIs are an effective treatment for this population, but have the major side effect of bone density loss, which can lead to increased fractures and long-term injury. To ensure patient safety, the National Comprehensive Cancer Network® (NCCN®) recommends that patients undergo bone mineral density (BMD) testing before starting treatment with AIs, and that women at increased risk for osteoporosis consider antiresorptive therapy, such as bisphosphonates, which slow or stop bone density loss.

Researchers at Medical College of Wisconsin, led by John Alan Charlson, MD, Associate Professor of Medicine, Division of Hematology and Oncology, studied women ages 67 and older to assess when and if they were undergoing the recommended bone density testing. According to the findings, as women aged—increasing their odds of osteoporosis and bone fracture—they were less likely to receive NCCN-recommended baseline testing. The study, Bone Mineral Density Testing Disparities among Breast Cancer Patients Prescribed Aromatase Inhibitors (AIs), is featured in the July issue of JNCCN - Journal of the National Comprehensive Cancer Network.

"This study highlights sub-optimal U.S. compliance with guideline recommendations for baseline BMD testing when starting AI therapy," said Dr. Charlson. "Older women, at higher risk for fractures in general, are least likely to get testing, and the slight increase in empiric treatment in no way closes the gap."

Looking at Medicare Part A, B, and D claims from 2006 through 2012, Dr. Charlson and fellow investigators found that approximately two-thirds of patients received recommended baseline BMD testing. Lower rates of baseline testing correlated to several factors, including race and income, but the most substantial correlation, the investigators found, was older age—86 years and older. In the study population, baseline BMD test rates fell progressively from 73 percent in women ages 67-70 to 51 percent in women over the age of 85.

"The oldest patients are most likely to be vulnerable to bone density loss, so BMD testing results may be especially important in this age group for analysis of risks and benefits of treatment, as well as to determine whom should be treated with bone-modifying agents," said Dr. Charlson.

Older women are at higher risk of osteoporosis and bone fracture. Hip fracture rates, according to the study, are seven times higher in women ages 70 and older than in other populations and higher comorbidity is also linked to these fractures. Although the oldest women in the study were least likely to receive BMD assessment, they did receive slightly higher rates of bisphosphonates as empiric therapy.

"While a larger number of older patients did receive bisphosphonates, this does not explain the disparities in bone density findings, or even substantially change our finding that attending to BMD was higher in lower risk younger women," said Dr. Charlson.

"These findings may be even more important in light of recent data from additional studies suggesting bone fracture rates may be even higher than previously recognized for women using adjuvant aromatase inhibitors," said Steven J. Isakoff, MD, PhD, Massachusetts General Hospital Cancer Center, Member of the NCCN Guidelines Panel for Breast Cancer. "In addition, many women may now be using aromatase inhibitors beyond five years, which may further increase the risk of fractures. This study highlights that, as a breast cancer community, we need to do a better job screening for bone health because with proper screening and treatment, many of these fractures can be prevented, particularly in the older patients at highest risk for fractures but who have the lowest rates of bone health screening."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New microfluidic device improves the separation of tumor cells and clusters from malignant effusions